$ANTHROPIC cleared Nasdaq's listing gate today, and the Binance perp is already quoting about 24% above the top of the filed IPO range. Which price should a trader believe?
Short answer: the approval is a calendar event, not a valuation. It settles where the shares will trade, not what they are worth.
What is now on the record:
- Anthropic's Nov 17 prospectus amendment, reported by the Economic Times, says its Class A stock was approved to list on the Nasdaq Global Select Market as ANT, with the range unchanged at $70 to $78 and 825 million shares in the offering.
- Nasdaq's trader notice, updated Nov 11, expects ANT to begin trading on Thursday, Nov 19, CUSIP 03703U107.
- CNBC reported on Nov 17, citing unnamed sources, that the deal is likely to price above that range, with order books closing at 4 p.m. ET.
Why the tape cares:
- An approval clears the venue; the price is set by the book. Anyone trading the perp is trading the expected first print, not the filing.
- On Binance, ANTUSDT last traded at $96.95 at 21:39 Kyiv, with a 24h high of $100.69 and a low of $94.12. That quote sits about 24% above the top of the filed range.
- The above-range talk is anonymous sourcing, not a filed number, and it can be right while the opening print lands far from the perp.
Dates and numbers I am tracking:
- Nov 19: the first Nasdaq trade, and whether it opens above $78.
- The priced range in the next prospectus amendment, against the $70 to $78 filed today.
- ANTUSDT around the open versus the implied share price. A gap alone will not tell me who was positioned which way.
My rule from cases like this: a listing approval is a date to mark, not a value to trust, so I keep the filing and the perp in separate columns.
#AnthropicClearedToListOnNasdaqAsANT #Write2Earn
If you trade ANT around the debut, would you weigh the filed range or the perp's own print more, and why?